Pooled across 34 studies data from 4.5+ million women showed that MHT use increased breast cancer odds by 15% versus non-use, ...

Clinical and payer strategies should treat GLP‑1 therapy as chronic for high-risk patients, addressing tolerability and cost ...

NHANES 2017–2018 elastography data (n=4102) linked to mortality showed 59 deaths over ~24 months; decedents were older and more likely to have diabetes. MASLD (CAP ≥274 dB/m) with diabetes carried ...

Pulmonary expert Noah Greenspan, DPT, discusses long COVID, early pandemic uncertainty, and how vaccination may help reduce ...

This episode, titled Optimizing Subcutaneous Therapies in NSCLC: Practical Integration, Patient Selection, and Workflow ...

SEER-Medicare analyses across 2005–2007, 2010–2012, and 2017–2019 showed persistently lower adjusted curative-treatment rates for Black vs White beneficiaries with early-stage NSCLC (all P<.001).

Humorous tone undermined engagement, whereas factual, straightforward framing aligned better with expectations for high-stakes vaccine communication. Disease-specific content performed best, with ...

Purposive-sampled Dutch interviews (n=23; median age 50; median MS duration 13 years) showed near-universal experience with physiotherapy and substantial occupational therapy exposure among ...

Clonal hematopoiesis in chronic lymphocytic leukemia is widespread, shaping cytopenias, cardiovascular risk, and chemotoxicity. As patients age on therapy for their chronic lymphocytic leukemia (CLL), ...

Fred D. Lublin, MD, discusses therapy sequencing, deescalation, health equity, and the future of multiple sclerosis (MS) care delivery. Effective multiple sclerosis (MS) treatment requires thinking ...

FDA authorization covers moderate-to-severe plaque psoriasis in adults and patients aged ≥12 years, expanding systemic options for adolescents. Icotrokinra is characterized as a first-in-class ...

In Personalized Selection of Immunotherapy Strategies in Metastatic NSCLC and Future Evidence Gaps, our experts delve into the following critical questions: We have now covered se ...